MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qad.0000000000001240

Медицинская библиотека · AIDS (London, England) · 2016

Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies.

Mulanovich Victor E, Desai Parth A, Popat Uday R

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

OBJECTIVE

HIV-positive patients with hematologic malignancies are frequently not considered for treatment with allogeneic hematopoietic stem cell transplantation (allo-HSCT) because of reported high morbidity and mortality with this procedure and scant published experience. Advances in HIV care and supportive care for allo-HSCT prompted us to review our experience since 2010, after we instituted multidisciplinary management of HIV-infected patients during the peritransplant period.

METHODS

We retrospectively reviewed the records of all HIV-positive patients who received allo-HSCT at our institution since 2010.

RESULTS

Five patients with various hematologic malignancies received allo-HSCT from matched related (two) or unrelated (three) donors since 2010. All patients received tenofovir (TDF)/emtricitabine in combination with either efavirenz (one) or raltegravir (four) and engrafted a median of 17 days after transplant. The most common infection was cytomegalovirus viremia, with six episodes in four patients, controlled with antivirals. There was no transplant-related mortality. Three patients relapsed 6, 7, and 13 months after transplant, and two were alive and well after 42 and 55 months. HIV viral load remained undetectable and CD4 cell count increased progressively. One patient had acute renal failure and improved with hydration and replacement of TDF with abacavir.

CONCLUSION

Our patients received allo-HSCT without transplant-related mortality or major infectious complications. Their HIV viral load remained undetectable without the use of protease inhibitors or need to discontinue antiretroviral therapy. One patient had acute renal failure that resolved after discontinuation of TDF. Our findings support considering selected HIV-infected patients for allo-HSCT when indicated for the management of their hematologic malignancies.

Для цитирования: Mulanovich Victor E, Desai Parth A, Popat Uday R. Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies.. AIDS (London, England). 2016. DOI: 10.1097/qad.0000000000001240.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.